Traws Pharma Financials
This page shows Traws Pharma (TRAW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Cash burn, not reported profit, still drives this development-stage business as liquidity tightens around ongoing research spending.
FY2025's positive net income of$9.2M sits opposite operating cash outflow of-$18.2M . Because cash ended the year at only$3.8M , the earnings turn did not improve self-funding capacity; the accounting result changed, but the business still operated like a program that consumes cash and depends on outside capital rather than customer receipts.
In FY2025, R&D spending of
Liquidity has tightened sharply: cash fell from
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Traws Pharma's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Traws Pharma has an operating margin of -640.7%, meaning the company retains $-641 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses.
Traws Pharma's revenue surged 1134.5% year-over-year to $2.8M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Traws Pharma carries a low D/E ratio of -17.88, meaning only $-17.88 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 79/100, indicating a strong balance sheet with room for future borrowing.
Traws Pharma's current ratio of 0.72 is below the typical benchmark, resulting in a score of 9/100. This tight liquidity could limit financial flexibility if cash inflows slow.
While Traws Pharma generated -$18.2M in operating cash flow, capex of $2.6M consumed most of it, leaving -$20.8M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Traws Pharma passes 2 of 9 financial strength tests. 1 of 3 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Traws Pharma generates $-1.98 in operating cash flow (-$18.2M OCF vs $9.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Traws Pharma generated $2.8M in revenue in fiscal year 2025. This represents an increase of 1134.5% from the prior year.
Traws Pharma's EBITDA was -$17.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
Traws Pharma reported $9.2M in net income in fiscal year 2025.
Traws Pharma earned $0.82 per diluted share (EPS) in fiscal year 2025. This represents an increase of 102.3% from the prior year.
Cash & Balance Sheet
Traws Pharma generated -$20.8M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 37.9% from the prior year.
Traws Pharma held $3.8M in cash against $0 in long-term debt as of fiscal year 2025.
Traws Pharma had 9M shares outstanding in fiscal year 2025. This represents an increase of 148.4% from the prior year.
Margins & Returns
Traws Pharma's operating margin was -640.7% in fiscal year 2025, reflecting core business profitability.
Traws Pharma's net profit margin was 328.7% in fiscal year 2025, showing the share of revenue converted to profit.
Capital Allocation
Traws Pharma invested $12.1M in research and development in fiscal year 2025. This represents a decrease of 5.5% from the prior year.
Traws Pharma invested $2.6M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 29.1% from the prior year.
TRAW Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | $2.7M+4694.7% | $57K+1.8% | $56K-1.8% | $57K0.0% | $57K+1.8% | $56K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $2.3M+0.9% | $2.3M-8.6% | $2.5M+34.9% | $1.9M-63.7% | $5.1M+29.0% | $4.0M+107.3% | $1.9M |
| SG&A Expenses | N/A | $1.7M+3.1% | $1.7M-38.6% | $2.8M-20.8% | $3.5M-0.1% | $3.5M+76.0% | $2.0M-41.1% | $3.4M |
| Operating Income | N/A | -$4.1M-224.7% | -$1.2M+76.0% | -$5.2M | N/A | -$8.5M | N/A | -$5.2M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | -$4.0M-333.0% | -$915K-104.3% | $21.5M | N/A | -$8.5M | N/A | -$5.0M |
| EPS (Diluted) | N/A | $-0.34-209.1% | $-0.11-105.3% | $2.09 | N/A | $-1.49 | $-20.52-246.6% | $-5.92 |
TRAW Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $10.6M-14.7% | $12.4M-20.3% | $15.6M-18.1% | $19.1M-23.6% | $25.0M+179.3% | $8.9M-52.2% | $18.7M+2.8% | $18.2M |
| Current Assets | $8.0M-17.1% | $9.6M-37.4% | $15.4M-18.5% | $18.9M-24.4% | $25.0M+179.6% | $8.9M-52.2% | $18.7M+2.9% | $18.2M |
| Cash & Equivalents | $3.8M-40.5% | $6.4M-50.9% | $13.1M-17.9% | $15.9M-25.3% | $21.3M+294.4% | $5.4M-68.0% | $16.9M+3.0% | $16.4M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $11.2M+42.4% | $7.9M+7.3% | $7.4M-43.7% | $13.1M-76.9% | $56.6M+415.9% | $11.0M-91.2% | $124.2M+921.7% | $12.2M |
| Current Liabilities | $11.1M+41.3% | $7.9M+7.3% | $7.4M-29.3% | $10.4M-9.8% | $11.5M+38.2% | $8.3M-15.8% | $9.9M+5.2% | $9.4M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$629K-113.8% | $4.5M-45.0% | $8.3M+37.7% | $6.0M+119.0% | -$31.6M-1455.8% | -$2.0M+98.1% | -$105.5M-1854.3% | $6.0M |
| Retained Earnings | -$640.0M-1.2% | -$632.5M-0.6% | -$628.6M-0.1% | -$627.7M+3.3% | -$649.2M-4.8% | -$619.2M-1.4% | -$610.8M-25.3% | -$487.6M |
TRAW Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.8M+31.2% | -$4.0M+32.9% | -$6.0M-10.0% | -$5.4M-34.6% | -$4.0M+64.8% | -$11.5M-16.5% | -$9.9M-122.7% | -$4.4M |
| Capital Expenditures | $0 | N/A | N/A | N/A | $0 | $0 | N/A | N/A |
| Free Cash Flow | -$2.8M | N/A | N/A | N/A | -$4.0M+64.8% | -$11.5M | N/A | N/A |
| Investing Cash Flow | $0 | N/A | N/A | N/A | $0 | $0 | N/A | N/A |
| Financing Cash Flow | $158K+354.8% | -$62K-102.0% | $3.1M+23707.7% | $13K-99.9% | $20.0M | $0 | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
TRAW Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | -45.7%+9082.4pp | -9128.1% | N/A | -14975.4% | N/A | -9307.1% |
| Net Margin | N/A | N/A | -33.5%-37735.2pp | 37701.8% | N/A | -14868.4% | N/A | -8898.2% |
| Return on Equity | N/A | -87.2%-76.1pp | -11.1%-369.2pp | 358.2% | N/A | N/A | N/A | -82.8% |
| Return on Assets | N/A | -31.8%-26.0pp | -5.9%-118.6pp | 112.7% | N/A | -94.8% | N/A | -27.4% |
| Current Ratio | 0.72-0.5 | 1.22-0.9 | 2.09+0.3 | 1.81-0.4 | 2.16+1.1 | 1.07-0.8 | 1.88-0.0 | 1.93 |
| Debt-to-Equity | -17.88-19.6 | 1.74+0.8 | 0.89-1.3 | 2.18+4.0 | -1.79+3.6 | -5.40-4.2 | -1.18-3.2 | 2.02 |
| FCF Margin | N/A | N/A | N/A | N/A | -7214.3%+12919.0pp | -20133.3% | N/A | N/A |
Note: Shareholder equity is negative (-$629K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.72), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Traws Pharma's annual revenue?
Traws Pharma (TRAW) reported $2.8M in total revenue for fiscal year 2025. This represents a 1134.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Traws Pharma's revenue growing?
Traws Pharma (TRAW) revenue grew by 1134.5% year-over-year, from $226K to $2.8M in fiscal year 2025.
Is Traws Pharma profitable?
Yes, Traws Pharma (TRAW) reported a net income of $9.2M in fiscal year 2025, with a net profit margin of 328.7%.
What is Traws Pharma's EBITDA?
Traws Pharma (TRAW) had EBITDA of -$17.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Traws Pharma's operating margin?
Traws Pharma (TRAW) had an operating margin of -640.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Traws Pharma's net profit margin?
Traws Pharma (TRAW) had a net profit margin of 328.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Traws Pharma's free cash flow?
Traws Pharma (TRAW) generated -$20.8M in free cash flow during fiscal year 2025. This represents a 37.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Traws Pharma's operating cash flow?
Traws Pharma (TRAW) generated -$18.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Traws Pharma's total assets?
Traws Pharma (TRAW) had $10.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Traws Pharma's capital expenditures?
Traws Pharma (TRAW) invested $2.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Traws Pharma spend on research and development?
Traws Pharma (TRAW) invested $12.1M in research and development during fiscal year 2025.
What is Traws Pharma's current ratio?
Traws Pharma (TRAW) had a current ratio of 0.72 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Traws Pharma's debt-to-equity ratio?
Traws Pharma (TRAW) had a debt-to-equity ratio of -17.88 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Traws Pharma's return on assets (ROA)?
Traws Pharma (TRAW) had a return on assets of 86.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Traws Pharma's cash runway?
Based on fiscal year 2025 data, Traws Pharma (TRAW) had $3.8M in cash against an annual operating cash burn of $18.2M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Traws Pharma's debt-to-equity ratio negative or unusual?
Traws Pharma (TRAW) has negative shareholder equity of -$629K as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Traws Pharma's Piotroski F-Score?
Traws Pharma (TRAW) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Traws Pharma's earnings high quality?
Traws Pharma (TRAW) has an earnings quality ratio of -1.98x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Traws Pharma?
Traws Pharma (TRAW) scores 31 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.